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Abstract: Asperger’s syndrome (AS) is under-recognized and may be misdiagnosed as 
schizophrenia in adults because of symptom overlap. Pharmacological treatment usually targets 
associated behavioral and mental symptoms rather than the actual core features of AS. We report 
a middle-aged male patient who, after many years of previous contact with mental health services, 
and on account of his psychotic symptoms and diagnosis of schizophrenia, was admitted to an 
inner-city acute psychiatric unit, where a primary diagnosis of AS was established for the ﬁ  rst 
time in his life. His impairing clinical features of AS improved markedly following treatment 
using aripiprazole, a novel atypical antipsychotic that acts as a partial agonist at dopamine D2 
receptors. As well as sharing clinical features, there is an overlap in underlying neurobiology 
of AS and schizophrenia, including dopamine dysfunction, that provides a rationale for using 
antipsychotics of this class in the clinical management not only of associated psychotic symptoms 
but also of the core features of AS itself.
Keywords: Asperger’s syndrome, autism spectrum disorders, schizophrenia, dopamine, 
aripiprazole, atypical antipsychotics 
Introduction
Asperger’s syndrome (AS), a pervasive neurodevelopmental disorder falling into 
the autism spectrum disorders, is relatively rare, but many sufferers may not receive 
appropriate care because AS core features could pass undetected or be misdiagnosed. 
The core features of AS are impaired non-verbal communication, restricted interests, 
and repetitive behavior (APA 2000). In contrast with autism, there is no clinically 
signiﬁ  cant delay in language acquisition. Intelligence is in the normal or superior 
range. Under-recognition, psychiatric co-morbidity, lack of treatment, and complicat-
ing social and behavioral factors can all contribute to critical clinical events requiring 
acute psychiatric admissions. 
We report a middle-aged male patient admitted to our acute psychiatric unit on 
account of his psychotic symptoms and impulsive behavior, whose original diagnosis 
of schizophrenia was reviewed and changed for a diagnosis of AS. His behavioral 
and mental symptoms, including impairing features of AS, responded to treatment 
using aripiprazole, a novel atypical antipsychotic that acts as a partial agonist at the 
dopamine D2 and serotonin 5HT1A receptors and as an antagonist at the serotonin 5HT2A 
receptors (Bowels et al 2003).
Case description
The patient, a 41-year-old male, was compulsorily admitted to our unit after 
having major anger outbursts at his hostel and threatening staff with a knife. He had 
previously received a diagnosis of schizophrenia on the basis of his history of unusual 
behaviors and symptoms such as social withdrawal, concrete thinking and paranoid Neuropsychiatric Disease and Treatment 2007:3(1) 174
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ideation. More recently he had been accusing the staff of 
“talking about him and calling him a paedophile”, probably 
an indication of auditory hallucinations, and been reported 
to repeatedly misinterpret routine conversations as abusive, 
triggering aggressive responses. He also had been using 
cannabis daily for many years. 
His developmental history revealed no delayed milestones. 
His parents divorced when he was 3 years old and his mother 
cared for him. At school he had excelled academically in 
languages but was clumsy at sport and formed no peer 
relationships, spending most of his time in the library reading 
about esoteric subjects. He felt marginalized, said to have 
been bullied, and was expelled from school at the age of 
18 after assaulting a pupil. There was no formal family 
history of mental illness but his father, a high achieving 
professional, was described as having a bad temper and being 
emotionally cold. Throughout his adult life he had tended to 
mistrust people. He had always found it difﬁ  cult to establish 
relationships and sustain employment. In recent years he 
had developed an intense interest in computer hardware and 
adopted a repetitive daily routine around this, reacting angrily 
if this was disrupted. 
He was referred to mental health services for the ﬁ  rst 
time aged 28 after he was dismissed from his job because 
of aggressive behavior. He was thought to be depressed 
and initially received psychotherapy, followed by a trial of 
ﬂ  uoxetine, which was discontinued due to side-effects. He 
was then referred to community mental health services and 
had been under their care ever since, refusing psychotropic 
medication whenever this was offered.
On admission he presented as a disheveled man who 
showed high levels of arousal and irritability and who was 
unwilling to co-operate with the interview, in the course of 
which he paced around the clinical room. He encroached 
on the interviewer’s personal space appearing intimidating. 
His speech was loud, sarcastic, and at times somewhat 
incoherent. He described his mood as angry but denied any 
sleep disturbance or changes in his energy levels. He was 
suspicious about the hospital staff and the motives behind 
his admission. He claimed that residents and staff at this 
hostel had been calling him a “paedophile” and making 
comments on child abuse with the speciﬁ  c aim of offending 
him. He spontaneously described being abused at school by 
a schoolteacher, but this had never been substantiated. 
On the ward he was noted to be socially withdrawn but 
his sleep and appetite were normal. His irritability abated 
after a few days, during which he received no medication but 
discontinued his cannabis smoking and responded to nursing 
care. Although no further incidents or aggressive outbursts 
were reported, he remained socially isolated, displaying ﬂ  at 
affect yet often evincing irritability and suspiciousness. He 
was subsequently observed to have awkward, ﬂ  eeting eye 
contact, a pedantic and almost theatrical use of language, 
and a remarkably unchanging facial mimicry. 
In the absence of any obvious continuing psychotic 
symptoms, and in view of both his encouraging response 
to the ward environment and clinical features that seemed 
to be traits rather than symptoms, we decided to review his 
diagnosis in the light of DSM-IV criteria for AS (APA 2000), 
all of which he seemed to meet. We further corroborated the 
diagnosis of AS by applying the Autism-Spectrum Quotient 
(AQ) (Baron-Cohen et al 2001), a self-rating scale, in which 
he scored 32, well above the suggested screening threshold 
of 26 for an autism-spectrum disorder. 
We then offered him psycho-education sessions where the 
diagnosis of AS was discussed, as well as reading material on 
this topic. He read the literature with interest and stated that 
the diagnosis was a useful way to understand his life-long 
social and behavioral difﬁ  culties. We also suggested that he 
could beneﬁ  t from drug treatment using an antipsychotic, 
as this could reduce his suspiciousness and persistently 
heightened levels of anxiety, in addition to enhancing his 
motivation, whereby he could acquire more control over his 
temper and social interactions.
With his consent, he was prescribed aripiprazole orally 
at an initial dose of 10 mg daily, which he tolerated well and 
was increased to 15 mg daily after 3 weeks. Two weeks after 
his initial dose the clinical team noted a favorable change 
in his overall behavior and psychological state as he began 
to interact with the other patients and actively engage in 
social activities, such as playing pool and chess and joining 
occupational therapy groups. The patient himself reported 
that he felt less anxious and less suspicious and more able 
to control his temper, enabling him to have more social 
conﬁ  dence and interact more with the clinical team. No 
adverse effects were observed. After 4 weeks a meeting 
was scheduled with his community mental health team and 
hostel staff to discuss his diagnosis and its implications, and 
to establish an aftercare plan that took these into account. 
His participation was remarkably insightful, particularly as 
he was able to accept that he had been misinterpreting other 
people’s behaviors and responding inappropriately to these. 
He was willing to return to the hostel and was discharged 
back to the care of his community team on aripiprazole Neuropsychiatric Disease and Treatment 2007:3(1) 175
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15 mg daily. Several months later he has remained well and 
adhering to his treatment, with no adverse effects or further 
incidents reported. 
Discussion
The estimated 4.7/10,000 prevalence of AS in the general 
population probably underestimates the true rate (Lauritsen 
et al 2004). AS may present with symptoms similar to 
those seen in schizophrenia, depressive disorders and some 
personality disorders. It may also co-exist with Tourette’s 
syndrome and many other clinical conditions (Gillberg and 
Billstadt 2000). This may partly explain why many sufferers 
receive a diagnosis of AS for the ﬁ  rst time only after reaching 
adulthood. AS may be associated with psychotic episodes 
(WHO 1992) and its clinical features may overlap with 
symptoms of schizophrenia, especially negative symptoms 
(Rausch et al 2005). This, and the fact that the former is 
more rare than the latter, may account for many sufferers 
who are misdiagnosed as having schizophrenia. Among 
2500 adults admitted to a psychiatric intensive care unit, 5 
(0.2%) received a diagnosis of AS for the ﬁ  rst time in their 
lives, which is 4 times the rate in the general population (Raja 
and Azzoni 2001). For this reason, Raja and Azzoni (2001) 
warn against overvaluing psychotic symptoms when speciﬁ  c 
features of AS are present. Additional features to substantiate 
a diagnosis of AS may include male gender, clumsiness, and 
obsessive-compulsive symptoms, as well as violent behavior 
and unusual restricted interests
The patient we described—an adult male of normal 
intelligence with a history of repetitive behavior, clumsi-
ness, impaired social functioning, aggressive outbursts, and 
restricted interests in a technically demanding pursuit—met 
virtually all DSM IV criteria for AS (APA 2000). The ideas 
of reference and auditory hallucinations he had experienced 
before admission probably obfuscated his AS features, thus 
culminating in his previous diagnosis of schizophrenia. 
However, cannabis abuse was probably a major contributing 
factor to his positive psychotic symptoms, which abated after 
he discontinued his cannabis consumption. Moreover, his 
features of AS, some of which could have been misconstrued 
as negative symptoms, had only become evident after his 
cannabis-induced psychotic symptoms had ameliorated.
Pharmacotherapy is not seen as the ultimate treatment 
of the core features of AS itself but has a deﬁ  nite place in 
the management of speciﬁ  c troubling symptoms (Bostic 
and King 2005). Treatment approaches may include 
antidepressants, mood stabilisers and antipsychotics. Yet, in 
addition to clinical similarities, the neurobiological overlap 
between AS and schizophrenia may provide a tentative 
rationale for the therapeutic use of antipsychotics in AS. Like 
schizophrenia, AS has been associated with soft neurological 
signs (Tani et al 2006), brain maturation abnormalities 
(Brambilla et al 2004) and abnormal central connectivity 
(Welchew et al 2005). Frith (2004) claimed that core features 
of AS are related to reduced activation and poor connectivity 
of the medial prefrontal and temporal cortex network, which 
is the neural substrate of intuitive mentalizing. Abnormal 
fronto-striatal pathways, resulting in defective sensorimotor 
gating, may lead to difﬁ  culties inhibiting repetitive thoughts, 
speech and actions (McAlonan et al 2002). Also like in 
schizophrenia, AS has been associated with dopamine 
dysfunction. Compared with normal subjects, AS patients 
were found to have increased presynaptic dopamine function 
in the striatum (Nieminen-von Wendt at al 2004).
Accordingly, dopamine-antagonist antipsychotics 
such as haloperidol and risperidone have been shown to 
signiﬁ  cantly improve repetitive behavior, aggression, and 
mood symptoms associated with pervasive developmental 
disorders (McDougle et al 1998). Risperidone has been 
shown to also ameliorate the negative symptoms spectrum 
associated with AS (Rausch et al 2005). However, the use of 
haloperidol is constrained by the risk of tardive dyskinesia, 
particularly in the long term, and the use of risperidone by 
the risk of weight gain and hyperprolactinaemia (British 
National Formulary 2005).
Some clinical features of our patient, such as his vulnerably 
to psychotic symptoms and lifelong suspiciousness, 
suggested that he could benefit from antipsychotic 
treatment. Aripiprazole is an atypical antipsychotic that has 
a low potential for inducing extrapyramidal side-effects, 
hyperprolactinaemia and weight gain (Bowles 2003) but, to 
our knowledge, no systematic study of using aripiprazole 
to treat AS has ever been conducted. Yet two ﬁ  ndings of a 
previous study in our unit, which had shown that aripiprazole 
can be effectively used to treat actively psychotic patients 
with schizophrenia, indicated that it could also be useful 
in AS. First, therapeutic responses to aripiprazole included 
the amelioration of negative symptoms (Dratcu et al 2006). 
Second, we found that aripiprazole could prove helpful in 
the treatment of disorders other than schizophrenia alone 
where dopamine dysfunction is also thought to play a role, 
like tardive dyskinesia. 
After receiving therapeutic doses of aripiprazole for two 
weeks, the patient experienced a range of positive clinical Neuropsychiatric Disease and Treatment 2007:3(1) 176
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changes, such as reduced levels of anxiety, arousal and 
suspiciousness, coupled with improved social interaction 
and self-control and better insight into his social and 
psychological difﬁ  culties. These were all recognized by the 
patient himself and sustained as he continued to comply with 
treatment, in the course of which no adverse reactions were 
noted. Similar ﬁ  ndings have been previously reported in a 
case involving an adult male with a history of intractable 
AS, who responded to aripiprazole after failing to respond 
to multiple psychological and pharmacological interventions 
(Staller 2003). Like in our patient, responses to aripiprazole 
included improved sociability and self-awareness, reduced 
rigidity/anxiety/irritability, and reduced preoccupation with 
esoteric interests.
Thus, our ﬁ  ndings seem to add to the clinical evidence 
that, as well as treating psychotic symptoms co-existing 
with AS, some antipsychotics like aripiprazole may 
potentially ameliorate core features of AS itself, a prospect 
that ﬁ  nds support in the neurobiological overlap of AS with 
schizophrenia. Unlike dopamine antagonists, aripiprazole 
may restore more functional levels of dopaminergic activity 
because its antagonistic action is dependent on the availability 
of dopamine itself. If this could explain the therapeutic effects 
of aripiprazole on the positive and negative symptoms of 
schizophrenia and in other dopamine-related syndromes, 
perhaps it may also explain the therapeutic effects of 
aripiprazole in AS, where dopamine dysfunction may 
likewise be implicated. 
Increasing awareness among clinicians about the 
diagnosis of AS, so that sufferers can be offered appropriate 
help at earlier stages, is by far the best option to prevent 
that they are further impaired by the psychiatric and other 
complications that may ensue. Psycho-education can prove 
invaluable to sufferers, but there are probably many who 
are likely to also beneﬁ  t from pharmacological approaches 
that can attenuate the pervasive and impairing features that 
they endure. In view of its mode of action and safety proﬁ  le, 
and also of the paucity of evidence on alternatives that can 
be effectively and safely used for this purpose, particularly 
in the long term, the use of aripiprazole in the treatment of 
AS warrants further scrutiny. Such studies are also likely to 
provide further insights into the pathogenesis and clinical 
management of AS. 
References
[APA] American Psychiatric Association. 2000. Diagnostic and Statistical 
Manual of Mental disorders, 4th ed—Text Revision (DSM IV—TR); 
Washington DC: American Psychiatric Press, Inc.
Anderson LT, Campbell M, Grega DM, et al. 1984. Haloperidol in the 
treatment of infantile autism: effects on learning and behavioral 
symptoms. Am J Psychiatry, 141:1195–202.
Baron-Cohen S, Wheelwright S, Skinner R, et al. 2001. The Autism spectrum 
Quotient (AQ): Evidence from Asperger syndrome/high functioning 
autism, males and females, scientists and mathematicians. J Autism 
Dev Disord, 31:5–17.
Berthier ML, Kulisevsky J, Asenjo B, et al. 2003. Comorbid Asperger 
and Tourette syndromes with localized mesencephalic, infrathalamic, 
thalamic, and striatal damage. Dev Med Child Neurol, 45:207–12.
Bostic JQ, King BH. 2005. Autism spectrum disorders: emerging 
pharmacotherapy. Expert Opin Emerg Drugs, 10:521–36.
Bowles TM, Levin GM. 2003. Aripiprazole: a new atypical antipsychotic 
drug. Ann Pharmacother, 37:687–94.
Brambilla P, Hardan AY, di Nemi SU, et al. 2004. The functional 
neuroanatomy of autism. Funct Neurol, 19:9–17.
British National Formulary. 2005. British Medical Association and Royal 
Pharmaceutical Society of Great Britain (eds). London.
Dratcu L, Olowu P, Hawramy M, et al. 2006. Aripiprazole in the acute 
treatment of male patients with schizophrenia: effectiveness, 
acceptability, and risks in the inner-city hospital setting. Neuropsychiatr 
Dis Treat, 2:191–7.
Frith U. 2004. Emanuel Miller lecture: confusions and controversies about 
Asperger syndrome. J Child Psychol Psychiatry, 45:672–86.
Gillberg C, Billstedt E. 2000. Autism and Asperger syndrome: coexistence 
with other clinical disorders. Acta Psychiatr Scand, 102:321–30.
Lauritsen MB, Pedersen CB, Mortensen PB. 2004. The incidence and 
prevalence of pervasive developmental disorders: a Danish population-
based study. Psychol Med, 34:1339–46.
McAlonan GM, Daly E, Kumari V, et al. 2002. Brain anatomy and 
sensorimotor gating in Aperger’s syndrome. Brain, 125:1594–606.
McDougle CJ, Holmes JP, Carlson DC, et al 1998. A bouble-blind, placebo-
controlled study of risperidone in adults with autistic disorder and other 
pervasive developmental disorders. Arch Gen Psychiatry, 55:633–41.
Nieminen-von Wendt TS, Metsahonkala L, Kulomaki TA, et al. 2004. 
Increased presynaptic dopamine function in Asperger syndrome. 
Neuroreport, 15:757–60.
Raja M, Azzoni A. 2001. Asperger’s disorder in the emergency psychiatric 
setting. General Hosp Psychiatry, 23:285–93. 
Rausch JL, Sirota EL, Londino DL et al. 2005. Open-label risperidone 
for Asperger’s disorder: negative symptom spectrum response. J Clin 
Psychiatry, 66:1592–7.
Staller JA. 2003. Aripiprazole ia an adult with Asperger disorder. Ann 
Pharmacother, 37:1628–31.
Tani P, Lindberg N, Appelberg B, et al. 2006. Clinical neurological 
abnormalities in young adults with Asperger syndrome. Psychiatry 
Clin Neurosci, 60:253–55.
Welchew DE, Aswhin C, Berkouk K, et al. 2005. Functional disconnectivity 
of the medial temporal lobe in Asperger’s syndrome. Biol Psychiatry, 
57:991–8.
[WHO] World Health Organization. 1992. ICD–10: The ICD–10 
Classiﬁ  cation of Mental and Behavioral Disorders: Clinical Descriptions 
and Diagnostic Guidelines. Geneva: WHO.